DAPAGLIFLOZIN,LINAGLIPTIN

Dapagliflozin and linagliptin combination is an antidiabetic medication approved by the US FDA to improve glycaemic control in adults with type 2 diabetes. Dapagliflozin received approval on 13 January 2014, and linagliptin on 2 May 2011. The combination works by enhancing insulin secretion and reducing glucose reabsorption.

Dapagliflozin and Linagliptin are used together to manage blood sugar levels in adults with type 2 diabetes. Dapagliflozin helps the kidneys remove excess glucose, while Linagliptin increases insulin production and reduces glucose production.

Dapagliflozin and Linagliptin combination is typically administered orally once daily, with or without food. It is important to follow the prescribed dosage and timing recommended by a healthcare provider. The tablet should be swallowed whole and not crushed or chewed.

Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them. Common side effects of Dapagliflozin and Linagliptin: Urinary tract infections Increased urination Nasopharyngitis (cold symptoms) Headache Back pain Serious side effects of Dapagliflozin and Linagliptin: Diabetic ketoacidosis Severe allergic reactions (rash, swelling, difficulty breathing) Kidney problems (decreased kidney function) Low blood pressure (dizziness, fainting)

Risk of Diabetic Ketoacidosis (DKA): Use with caution in patients with type 1 diabetes or those with significantly high blood sugar, as they may be at higher risk of DKA. Kidney Impairment: Dapagliflozin may impair kidney function, and the combination should be used with caution in patients with reduced kidney function. Volume Depletion: Dapagliflozin can cause dehydration and low blood pressure, potentially leading to dizziness, fainting, or kidney issues. Use cautiously in patients with dehydration or heart conditions. Urinary Tract Infections (UTIs): Patients may be at increased risk of UTIs due to increased glucose in the urine. Monitor for symptoms such as burning or pain during urination. Pancreatitis: Linagliptin may increase the risk of pancreatitis (inflammation of the pancreas). Monitor for symptoms such as severe abdominal pain, nausea, or vomiting. Allergic Reactions: Serious allergic reactions, such as rash, swelling, and difficulty breathing, may occur and require immediate medical attention. Bladder Cancer Risk: Long-term use of dapagliflozin may increase the risk of bladder cancer. Exercise caution in patients with a history of bladder cancer or those at higher risk. Pregnancy and Breastfeeding: The safety of the combination during pregnancy and breastfeeding has not been established. Avoid unless clearly necessary, and consult a healthcare provider.

Take precautions when using Dapagliflozin and Linagliptin by regularly monitoring kidney function, as the medication can impact renal health. Stay cautious if you have a history of urinary tract infections, dehydration, or heart conditions. Ensure proper hydration and report any unusual symptoms, such as abdominal pain or breathing difficulties, to your healthcare provider.

Follow your healthcare provider's instructions carefully regarding dosage and timing of Dapagliflozin and Linagliptin. Maintain adequate hydration and monitor for side effects including urinary tract infections or dizziness. Kidney function and overall health require regular assessment through scheduled check-ups. Inform your doctor of all other medications and existing medical conditions to identify potential drug interactions.

1. Jain A, Vispute A, Dange A, Naskar A, Mondal A, Vivekanand B, Sharma B, Varade D, Shukla D, Bhatia G, Chaudhari H, Ram Babu K, Gavali O, Sorate S, Bhanushali S, Kothari V, Khandelwal V, Sharma A, Pawar R, Mayabhate M, Shahavi V, Rajput A, Jaiswal M. A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin. https://pubmed.ncbi.nlm.nih.gov/37957465/ 2. Hong JH, Kim MJ, Min KW, Won JC, Kim TN, Lee BW, Kang JG, Kim JH, Park JH, Ku BJ, Lee CB, Kim SY, Shon HS, Lee WJ, Park JY. Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study. https://pubmed.ncbi.nlm.nih.gov/39375869/ 3. Dharmalingam M, Kumar Sharma S, Prakash V, Maiti A, Kumar R, Murthy LSS, Ramanathan B, Maheshwari S, Naik Kethavath S, Ogale D, Bachubhai PVK, Sonawane AB, Shah V, Suresh M, Chakraborty S, Kumar Manjunath K. Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin. https://pubmed.ncbi.nlm.nih.gov/38738005/